Neuraxis Inc（NRXS）股票分析

AI 分析 of Neuraxis Inc (NRXS)

持有

Neuraxis Inc (NRXS) is currently priced at 6.60, which is near its 52-week low of 2.21 and significantly below its 52-week high of 9.33. The RSI is at 24.60, indicating the stock is oversold, which could suggest a potential rebound. However, the company has a forward P/E of 0 and has reported consistent net losses, with a net income of -2,277,249 in Q2 2026. The significant insider and hedge fund activity is neutral, indicating no strong buying or selling pressure from these groups. The main risk is the company's ongoing losses, as evidenced by a net margin of -108.14% in Q2 2026, which could hinder its ability to recover in the short term.

估值指標

Neuraxis Inc（NRXS）目前預期本益比為 0.00，5 年平均預期本益比為 -17.02。

預期本益比

高估

5 年均值 P/E

-17.02

目前P/E

0.00

高估

-4.70

低估

-29.35

預期 EV/EBITDA

低估

5 年均值 EV/EBITDA

-1.23

目前EV/EBITDA

-3.16

高估

0.30

低估

-2.76

預期股價營收比

合理

5 年均值 P/S

2.88

目前P/S

3.88

高估

4.42

低估

1.33

Alphio AI 對 NRXS 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。

樂

樂觀

樂觀 · 25%NRXS

$3.72

情境價格

基

基準

基準 · 50%NRXS

$2.45

情境價格

悲

悲觀

悲觀 · 25%NRXS

$1.57

情境價格

NRXS 常見問題 —— 由 Alphio AI 解答

Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies for chronic and debilitating conditions in gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. Its IB-Stim, is a Percutaneous Electrical Nerve Field Stimulation (PENFS) technology intended to be used in patients eight years and older with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. Its second product, RED (Rectal Expulsion Device), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge to defecate at lower volumes of distension. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Neuraxis Inc (NRXS) is currently priced at 6.60, which is near its 52-week low of 2.21 and significantly below its 52-week high of 9.33. The RSI is at 24.60, indicating the stock is oversold, which could suggest a potential rebound. However, the company has a forward P/E of 0 and has reported consistent net losses, with a net income of -2,277,249 in Q2 2026. The significant insider and hedge fund activity is neutral, indicating no strong buying or selling pressure from these groups. The main risk is the company's ongoing losses, as evidenced by a net margin of -108.14% in Q2 2026, which could hinder its ability to recover in the short term.